Mycotic Pulmonary Artery Aneurysm Mimicking a Rasmussen Aneurysm

Stephanie C Cajigas-Loyola1, Ricky L Miller1, Bradley Spieler1

  • 1Department of Radiology, Louisiana State University Health Sciences Center, New Orleans, LA.

Ochsner Journal
|March 22, 2018
PubMed
Abstract

Insights

Rare pulmonary artery mycotic aneurysms require prompt diagnosis and treatment to prevent rupture. This case highlights the importance of considering this diagnosis in patients with bacteremia, especially when symptoms mimic other conditions like Rasmussen aneurysm.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Radiology

Background:

  • Mycotic aneurysms of the pulmonary arteries are rare, with Staphylococcus and Streptococcus species being common pathogens.
  • These aneurysms often present secondary to procedural complications and carry significant morbidity and mortality if not treated promptly.

Observation:

  • A 37-year-old male presented with bacteremia and bronchopneumonia, complicated by a pulmonary artery mycotic aneurysm.
  • The clinical presentation mimicked a Rasmussen aneurysm, necessitating careful diagnostic evaluation.

Findings:

  • Computed tomography (CT) enables accurate and timely diagnosis of mycotic aneurysms.
  • Interventional embolization offers a rapid, minimally invasive, and curative treatment option.

Implications:

  • Mycotic aneurysms should be considered in patients with risk factors like intravenous drug use, bacterial endocarditis, or immunocompromise.
  • Distinguishing mycotic aneurysms from Rasmussen aneurysms is crucial, requiring thorough microbiologic assessment to guide appropriate management and prevent life-threatening rupture.

Related Concept Videos

Aneurysm I: Introduction01:30

Aneurysm I: Introduction

An aortic aneurysm is a localized outpouching or dilation at a weak point in the artery wall. It may involve different parts of the aorta, such as the abdominal aorta, aortic arch, or thoracic aorta.Etiological factorsSeveral disorders are associated with aortic aneurysms.Congenital causes, such as primary connective tissue disorders like Marfan syndrome, impact the integrity and strength of connective tissues, notably affecting the aorta. Marfan syndrome is a genetic disorder that specifically...
440
Aneurysm IV: Nursing Management01:22

Aneurysm IV: Nursing Management

Vigilant monitoring for aneurysm rupture is essential for patients undergoing aortic surgery.Preoperative Nursing ManagementContinuously monitor the patient for manifestations of aneurysm rupture, such as pallor, weakness, tachycardia, hypotension, abdominal, back, groin, or periumbilical pain, changes in consciousness, and a pulsating abdominal mass. Regularly assess the patient's peripheral pulses.Instruct the patient to consume a clear liquid diet the day before surgery and administer...
483
Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
316
Aneurysm II: Clinical Manifestations and Diagnostic Studies01:21

Aneurysm II: Clinical Manifestations and Diagnostic Studies

Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
378
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
625
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
484